By IDSE News Staff
The FDA approved taurolidine-heparin catheter lock solution (CLS; Defencath, CorMedix) to reduce catheter-related bloodstream infections (CRBSIs) in adults with renal failure who are receiving chronic hemodialysis through a central venous catheter (CVC).
Defencath is the first and only FDA-approved antimicrobial CLS in the United States. Defencath is indicated in this limited and specific patient population.
The FDA approval of Defencath was supported by results from the